How are Khavinson bioregulators different from standard peptides?

Name: Bronchogen
Price: 179 USD
Availability: InStock

Khavinson bioregulators are dipeptides or tripeptides designed to match the reading frame of specific gene regulatory regions. They are thought to act as gene expression modulators by interacting with histone-DNA complexes in target tissue nuclei, rather than by binding surface receptors. This makes them fundamentally different in mechanism from most research peptides.

Bronchogen

Peptide bioregulator developed by Vladimir Khavinson targeting lung tissue. Studied for organ-specific gene expression normalisation and age-related functional

Anti-AgingRecovery

● In Stock

Select Variant

Quantity (vials)

Buy more, save more

—

1+ vials

−5%

3+ vials

−10%

5+ vials

−20%

10+ vials

Total Price

$180

For research & laboratory use only. Not for human consumption.

Administration Route

Subcutaneous injection

Lung Tissue Peptide

Khavinson tetrapeptide for bronchial epithelium health

Respiratory Function

Supports mucociliary clearance and bronchial cell regeneration

Pulmonary Ageing

Addresses age-related decline in lung tissue function

Effect Profile

Based on primary research mechanisms

Cellular Longevity

Collagen Synthesis

Oxidative Protection

Energy Restoration

Mechanism of Action

Bronchogen is a short peptide bioregulator from the Khavinson series, designed to act as a complementary DNA sequence that penetrates cell nuclei and binds to gene promoter regions controlling bronchial epithelium, pulmonary function, and respiratory tract tissue maintenance. By interacting with nuclear chromatin, it normalises the expression of genes involved in cell cycle regulation and tissue homeostasis, correcting age-associated downregulation of maintenance programmes in the target tissue.